A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance - PubMed
3 hours ago
- #pancreatic cancer
- #targeted therapy
- #tumor resistance
- A triple targeted combination therapy of KRAS, EGFR, and STAT3 inhibitors induces complete and lasting regression of pancreatic ductal adenocarcinoma (PDAC) in mouse models, preventing tumor resistance for over 200 days post-treatment.
- The therapy is effective in genetically engineered mouse models and patient-derived xenografts (PDX), showing no tumor relapses and is well-tolerated in these preclinical studies.
- The approach addresses key signaling pathways (downstream, upstream, and orthogonal to KRAS) to overcome resistance seen with single-agent RAS inhibitors, guiding potential clinical trials for PDAC treatment.